Literature DB >> 16010871

Pharmacokinetic and pharmacodynamic of irbesartan in renal hypertensive dogs under non-steady-state and steady-state conditions.

Xiao-Hui Huang1, Fu-Rong Qiu, Hai-Tang Xie, Jun Li.   

Abstract

The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of irbesartan in renal hypertensive dogs under non-steady-state and steady-state conditions using pharmacokinetic-pharmacodynamic (PK/PD) modeling. Drugs were administered intragastrically to renal hypertensive dogs, plasma drug concentration was determined by HPLC method and Pharmacologic effects, including SBP, DBP, dp/dtmax and LVSP, were measured simultaneously. AT II, Aldosterone (ALD) and Endothelin (ET) were also used as measurement of effect. The PK and PD data were quantitatively analyzed according to the PK/PD model theory. The pharmacokinetic profiles of irbesartan conformed to a two-compartment open model. There was hysteresis loops between effects and plasma concentrations under non-steady-state condition. The relationship between effects and effect compartment concentrations (Ce) could be represented by the Sigmoid-Emax model. The Hysteresis loops disappeared under steady-state condition with more rapidly attainment of maximum concentration and effect. There were certain difference of pharmacokinetic and pharmacodynamic properties between non-steady-state and steady-state condition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010871     DOI: 10.1007/BF03226417

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 2.  A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?

Authors:  Mark Greathouse
Journal:  Congest Heart Fail       Date:  2002 Nov-Dec

3.  Pharmacokinetic-pharmacodynamic modeling of daurisoline and dauricine in beagle dogs.

Authors:  Shao-Jun Shi; Hui Chen; Shi-Fen Gu; Fan-Dian Zeng
Journal:  Acta Pharmacol Sin       Date:  2003-10       Impact factor: 6.150

Review 4.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.

Authors:  B Meibohm; H Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  1997-10       Impact factor: 1.366

Review 5.  Clinical differences among angiotensin II receptor antagonists.

Authors:  G Mancia
Journal:  Blood Press Suppl       Date:  2001

6.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.

Authors:  E Fuseau; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

7.  Simultaneous pharmacokinetic and pharmacodynamic modeling.

Authors:  W A Colburn
Journal:  J Pharmacokinet Biopharm       Date:  1981-06

8.  Pharmacokinetic-pharmacodynamic modeling of metoprolol stereoisomers in spontaneously hypertensive rat.

Authors:  X X Yin; Y D Zhang; J P Luo; X P Huang; J P Shen; Y Ding; D K Huang
Journal:  Zhongguo Yao Li Xue Bao       Date:  1997-03

9.  The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.

Authors:  J Rosenstock; L Rossi; C S Lin; D MacNeil; M Osbakken
Journal:  J Clin Pharm Ther       Date:  1998-12       Impact factor: 2.512

  9 in total
  2 in total

1.  PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions.

Authors:  Xiao-Hui Huang; Jun Li; Fu-Rong Qiu; Hai-Tang Xie; Ji-Han Huang; Jian-Chun Li; Qing-Shan Zheng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Oct-Dec       Impact factor: 2.441

2.  Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.

Authors:  Santosh Kumar Puttrevu; Rachumallu Ramakrishna; Manisha Bhateria; Moon Jain; Kashif Hanif; Rabi Sankar Bhatta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.